Non-invasive biosensors are novel diagnosis devices, which do not require any invasive procedure for detection of any substance or disease. This technology uses sweat, tears, or saliva for diagnostic purpose. Glucose monitoring and blood analytes monitor have become available in the market, which uses non-invasive biosensors. Moreover, there are many non-invasive biosensors under development and under clinical trial for new applications such as cancer and blood alcohol concentration detection.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1704
Increasing approval and launches of novel non-invasive biosensors is expected to boost growth of global non-invasive biosensors market in the near future. For instance, in 2016, Nemaura Medical, Inc. received CE approval in the European Union for its latest sugarBEAT, a minimally invasive wireless continuous glucose monitor. Moreover, in 2013, Integrity Applications Inc. received CE marking for its new GlucoTrack DF-F device, a non-invasive blood glucose monitoring device. Increasing research and development activities for developing novel non-invasive biosensors is also expected to drive growth of market in the near future. For instance, in 2017, Mclean Hospital announced that LabPatch-alcohol, its non-invasive skin patch that detects blood alcohol concentration, is in clinical trial. LabPatch-alcohol is in early Phase 1 stage of clinical trial. Furthermore, increasing prevalence of diabetes is also expected to increase demand for non-invasive biosensors for diagnosis. According to the World Health Organization (WHO), 2014, around 8.5% of adults aged 18 and above accounting for 422 million adults were suffering from diabetes worldwide.
Increasing approval for non-invasive biosensor devices is expected to drive growth of the global market
In 2016, Nemaura Medical, Inc. received CE approval in the European Union for its sugarBEAT, a minimally invasive wireless continuous glucose monitor. SugarBEAT CGM system is available in the form of sensor patch and provides glucose readings on a standalone reader, smart watch or smart phone app via Bluetooth. In March 2018, Nemaura Medical, Inc. expanded its manufacturing facilities for large scale production of its new SugarBEAT CGM system. The company is expected to launch its product in the U.K. in the near future. The approval and launche of such novel devices is expected to create a lucrative environment for growth of global non-invasive biosensor market in the near future.
Increasing research and development and robust pipeline of novel non-invasive biosensors is expected to drive growth of the non-invasive biosensor market
Increasing research and development and a robust pipeline of novel non-invasive biosensors is expected to drive growth of the global non-invasive biosensor market in the near future. For instance, MediWise Ltd.—a U.K.-based company—has its product GlucoWise in clinical trial. GlucoWise is a non-invasive glucose monitor device and is expected to be launched in 2018. In 2017, researchers from University of Cincinnati developed a non-invasive biosensor, which uses chemical stimulant to produce sweat and uses sweat to monitor biometrics.
Increasing prevalence of diabetes is expected to increase demand for non-invasive biosensors for diagnosis
According to World Health Organization (WHO), 2014, around 8.5% of adults aged 18 and above accounting for 422 million adults were suffering from diabetes worldwide. According to National Diabetes Statistics Report 2017 published by Centers of Disease Control and Prevention (CDC), around 9.4% of the population in the U.S., which includes all age groups i.e., pediatric, adults, and geriatric population accounting for 30.3 million people are suffering from diabetes whereas 33.9% are diagnosed with pre-diabetes. Increasing prevalence of diabetes is expected to increase demand for novel diagnostic devices such as non-invasive glucometer and this is expected to drive growth of global non- invasive biosensor market.
Furthermore, key players in the market are participating in various conference and symposium, in order to showcase their novel non-invasive biosensors. For instance, in 2017, Integrity Applications Inc. exhibited its new GlucoTrack at American Diabetes Association’s 77th Scientific Sessions held at San Diego, U.S.
Buy Now This Report: https://www.coherentmarketinsights.com/insight/buy-now/1704
Key players operating in the non-invasive biosensors market include Nemaura Medical, Inc., MediWise Ltd., Integrity Applications Inc., OrSense, Medtronic Plc, GE Healthcare, Philips Healthcare, Akers Biosciences, Inc. and Abbott Laboratories.
This post was originally published on Trading Herald